Call  +41 61 926 6040
Fax +41 61 926 6049
Toggle Nav
My Cart
Search
Advanced Search
Account
Settings
Toggle Nav

AdipoGen Life Sciences

Progranulin (human) ELISA Kit

CHF 610.00
In stock
AG-45A-0018YEK-KI0196 wellsCHF 610.00
AG-45A-0018YTP-KI012 x 96 wellsCHF 1'100.00
Call  +41 61 926 6040
Fax  +41 61 926 6049
Contact Us!
Loading...
Figure 1: Standardcurve
More Information
Product Details
Synonyms Proepithelin; PEPI; PC Cell-derived Growth Factor
Product Type Kit
Properties
Application Set Quantitative ELISA
Specificity Detects human progranulin.
Crossreactivity Human
Quantity 1 x 96 wells
2 x 96 wells (Twin Plex)
Sensitivity 32pg/ml
Range 0.063 to 4ng/ml
Sample Type Cell Culture Supernatant
Plasma
Serum
Urine
Assay Type Sandwich
Detection Type Colorimetric
Other Product Data NOTE: The TwinPlex size is supplied as 2 independent SinglePlate Kits from the same lot.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice After standard reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Plate and reagents should reach room temperature before use.
Use/Stability 12 months after the day of manufacturing. See expiry date on ELISA Kit box.
Documents
Manual Download PDF
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Progranulin (PGRN) is a widely expressed pluripotent growth factor that plays a role in processes such as development, wound repair, and inflammation by activating signaling cascades that control cell cycle progression and cell motility. Its function in the central nervous system is of interest, as mutations in the PGRN gene were found in cases of frontotemporal degeneration (FTLD). In addition, PGRN has also been linked to tumorigenesis. New cutting-edge publications have shown that progranulin might be a biomarker not only for FTLD but also for other types of Alzheimer‘s disease (AD). This new data even suppose the potential of progranulin to be a biomarker for MCI (Mild Cognitive Impairment), which would be a hallmark in AD research. Additionally, PGRN is described as a new ligand of TNF receptors and a potential therapeutic against inflammatory diseases like arthritis.

Progranulin expression in plasma predicts GRN mutations status, independently of symptom onset proximity. Progranulin loss-of-function mutations are among the most frequent genetic causes, responsible for 20% of familial FTLD. If a patient carries a mutation in the progranulin gene, it can be detected using AdipoGen's Progranulin (human) ELISA Kit. This is the only and unique kit on the market detecting all mutations of Progranulin [Reference 58].

Product References
  1. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration: R. Ghidoni, et al.; Neurology 71, 1235 (2008)
  2. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia: R. Rademakers, et al.; Hum. Mol. Genet. 17, 3631 (2008)
  3. Serum progranulin concentrations may be associated with macrophage Infiltration into omental adipose tissue: B.S. Youn, et al.; Diabetes 58, 627 (2009)
  4. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members: N. Finch, et al.; Brain 132, 583 (2009)
  5. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease: M. Carecchio, et al.; J. Neurol. Sci. 287, 291 (2009)
  6. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes: M. De Riz, et al.; Neurosci. Lett. 469, 234 (2010)
  7. Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study: E.C. Schofield, et al.; J. Alzheimers Dis. 22, 981 (2010)
  8. A Novel Progranulin Mutation Causing Frontotemporal Lobar Degeneration with Heterogeneous Phenotypic Expression: G. Rossi, et al.; J. Alzheimers Dis. 23, 7 (2010)
  9. Pathogenic cysteine mutations affect progranulin function and production of mature granulins: J. Wang, et al.; J. Neurochem. 112, 1305 (2010)
  10. Microglial upregulation of progranulin as a marker of motor neuron degeneration: T. Philips, et al.; J. Neuropathol. Exp. Neurol. 69, 1191 (2010)
  11. A novel progranulin mutation causing frontotemporal lobar degeneration with heterogeneous phenotypic expression: G. Rossi, et al.; J. Alzheimers Dis. 23, 7 (2011)
  12. rs5848 polymorphism and serum progranulin level: G.Y. Hsiung, et al.; J. Neurol. Sci. 300, 28 (2011)
  13. Association of TMEM106B Gene Polymorphism With Age at Onset in Granulin Mutation Carriers and Plasma Granulin Protein Levels: C. Cruchaga, et al.; Arch. Neurol. 68, 581 2011
  14. Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis: M. Vercellino, et al.; Mult. Scler. 17, 1194 (2011)
  15. Soluble Beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis: Steinacker, et al.; PLoS One. 6, e23600 (2011)
  16. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients: P. Bossù, et al.; J. Neuroinflammation 8, 65 (2011)
  17. Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression: T. Wex, et al.; BMC Gastroenterol. 11, 63 (2011)
  18. Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred: A.M. Pietroboni, et al.; J. Alzheimers Dis. 24, 253 (2011)
  19. Progranulin Genetic Screening in Frontotemporal Lobar Degeneration Patients From Central Italy: S. Bagnoli, et al.; Cell Mol. Neurobiol. 32, 13 (2011)
  20. Optimal Plasma Progranulin Cutoff Value for Predicting Null Progranulin Mutations in Neurodegenerative Diseases: A Multicenter Italian Study: R. Ghidoni, et al.; Neurodegener. Dis. 9, 121 (2012)
  21. Prevalence of frontotemporal lobar degeneration in an isolated population: the Vallecamonica study: N. Gilberti, et al.; Neurol. Sci. 33, 899 (2012)
  22. Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD: B. Borroni, et al.; Neurobiol. Aging. 33, 2506 (2012)
  23. Mining the Gastric Cancer Secretome: Identification of GRN as a Potential Diagnostic Marker for Early Gastric Cancer: H. Loei, et al.; J. Proteome Res. 11, 1759 (2012)
  24. Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention: M. Blueher, et al.; Diabetes Care 35, 342 (2012)
  25. Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia: O. Dols-Icardo, et al.; Neurobiol. Aging 33, 1851 (2012)
  26. Strikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage: K.R. Smith, et al.; Am. J. Hum. Genet. 90, 1102 (2012)
  27. C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic: A. Wojtas, et al.; Am. J. Neurodegener. Dis. 1, 107 (2012)
  28. Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study: D.H. Koo, et al.; PLoS One 7, e39880 (2012)
  29. Clinical, Neuropathological, and Genetic Characteristics of the Novel IVS9+1delG GRN Mutation in a Patient with Frontotemporal Dementia: R. Taipaa, et al.; J. Alzheimers Dis. 30, 83 (2012)
  30. Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations: A. Arighi, et al.; J. Alzheimers Dis. 31, 447 (2012)
  31. Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort: A. Antonell, et al.; J. Alzheimers Dis. 31, 581 (2012)
  32. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study: D.H. Koo, et al.; PLoS One 7, e39880 (2012)
  33. Circulating Progranulin Levels in Women with Gestational Diabetes Mellitus and Healthy Controls During and After Pregnancy: J. Todoric, et al.; Eur. J. Endocrinol. 167, 561 (2012)
  34. Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in Southern Italy: L. Bernardi, et al.; Neurobiol. Aging 33, 2948 (2012)
  35. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways: A.S. Chen-Plotkin, et al.; J. Neurosci. 32, 11213 (2012)
  36. Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia: C. Alquezara, et al.; Neurobiol. Aging 33,429.e7 (2012)
  37. Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort: S.C. Jin, et al.; Alzheimers Res. Ther. 4, 34 (2012)
  38. Structural Brain Signature of FTLD Driven by Granulin Mutation: M. Bozzali, et al.; J. Alzheimers Dis. 33, 483 (2012)
  39. Progranulin antibodies in autoimmune diseases: L. Thurner, et al.; J. Autoimmun. 42, 29 (2013)
  40. Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration: D. Galimberti, et al.; Neurol. Sci. 34, 899 (2013)
  41. GRN Variant rs5848 Reduces Plasma and Brain Levels of Granulin in Alzheimer's Disease Patients: A. Kamalainen, et al.; J. Alzheimers Dis. 33, 23 (2013)
  42. Implication of Progranulin and C1q/TNF-Related Protein-3 (CTRP3) on Inflammation and Atherosclerosis in Subjects with or without Metabolic Syndrome: H.J. Yoo, et al.; PLOS One 8, e55744 (2013)
  43. Screening for progranulin mutations by serum protein dosage in common neurodegenerative disorders: E. Rodriguez-Rodriguez, et al.; Parkinson. Rel. Disord. 19, 768 (2013)
  44. Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration: H.-H. Chiang, et al.; Eur. J. Hum. Gen. 21, 1260 (2013)
  45. Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis: L. Thurner, et al.; Arthritis Res. Ther. 15, R211 (2013)
  46. Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects: K. Mirzaei, et al.; Diabetol. Metabol. Syndr. 5, 79 (2013)
  47. Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris: K.M. Choi, et al.; Cardiovasc. Diabetol. 13, 14 (2014)
  48. Circulating progranulin level is associated with visceral fat and elevated liver enzymes: Significance of serum progranulin as a useful marker for liver dysfunction: Y. Tanaka, et al.; Endocr. J. 61, 1191 (2014)
  49. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation: G. Flehmig, et al.; PLoS One 9, e99785 (2014)
  50. Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis: L.A. Cerezo, et al.; Mediators Inflamm. 2015, 740357 (2015)
  51. Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD: E. Feneberg, et al.; J. Neural. Transm. 123, 289 (2016)
  52. Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study: J. Johnson, et al.; Clin. Rheumatol. 36, 507 (2016)
  53. Reduced miR-659-3p levels correlate with progranulin increase in hypoxic conditions: implications for frontotemporal dementia: P. Piscopo, et al.; Front. Mol. Neurosci. 9, 31 (2016)
  54. Prosaposin is a regulator of progranulin levels and oligomerization: A.M. Nicholson, et al.; Nat. Commun. 7, 11992 (2016)
  55. Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features: C.M. Karch, et al.; Neurobiol. Aging 38, 215.e1 (2016)
  56. Progranulin mutation analysis: Identification of one novel mutation in exon 12 associated with frontotemporal dementia: P.M. Aswathy, et al.; Neurobiol. Aging 39, 218.e1 (2016)
  57. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration: J. Goossens, et al.; Alzheimer's Res. Ther. 10, (2018)
  58. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience: L. Sellami, et al.; Neurobiol. Aging 91, 167.e1 (2020)
  59. Progranulin promotes immune evasion of pancreatic adenocarcinoma through regulation of MHCI expression: P.F. Cheung, et al.; bioRxiv (Preprint) (2021)
  60. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up: M. Bruzova, et al.; Nature Sci. Rep. 11, 10837 (2021)
  61. Association of serum uromodulin with adipokines in dependence of type 2 diabetes: C. Then, et al.; Cytokine 150, 155786 (2022)
  62. Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias: F. Meda, et al.; Clin. Chem. Lab. Med. 61, 2195 (2023)
  63. A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors: I.J. Swift, et al.; Alzheimers Res. Ther. 16, 66 (2024) (Systemtatic Review/Meta-Analysis)
Related Products
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.